Liver cancer (cancer) in remedy big advance

Liver cancer (cancer) in remedy big advance


　Molecular target medicine sorafenib [sorahuenibu] (trade name: When Nexavar, the Bayer corporation, * in the Japanese country during application approval applying of the kidney cell cancer), the advance liver (the cell) you can see the effect where is high to the cancer, the result of clinical test SHARP trial, the American cancer remedy academic society which is held in Chicago (ASCO) was announced with annual meeting. When the same medicine to the advance liver cancer patient is prescribed, you say that lifetime 44% extended in comparison with the patient who is not prescribed.

　Research the American [mauntosainai] medical science university which does (New York) according to Joseph Llovet doctor, as for the systemic remedy which extends the lifetime of the liver cancer patient you say that this is unprecedented. Passing the randomization engine bench test which exceeds 100 with the research which spans 30, it means that those which should become new standard remedy of the liver cancer patient finally appear. You have expressed that the American cancer association (ACS) Len Lichtenfeld doctor, this remedy probably will change the standard of medical care.

　As for the liver cancer at 3rd rank of cause of the death with the cancer of the world, the case which from diagnosis dies within 1 years it is many. 40% of the liver cancer (Asia and Sahara from here in Africa south 80%), it is diagnosed at the stage which was advanced. Surgical operation and radiotherapy and chemotherapy are done, but the systemic remedy which is by the medicine (the remedy which inserts the medicine in the blood style) so far it did not exist, standard cure was not established. sorafenib with the medicine of tablet type, in the United States is approved already as the advance kidney cancer remedy, (* the possibility that application to the liver cancer is approved during June). In the meeting, the test result to several cancer was announced other than the same medicine.

　In the latest research, 1 day 2 time dosage group and [purasebo] of sorafenib 400mg (the false medicine) to allot 602 advance liver cancer patients, to the group randomly, 6 monthly dosages. As for the [purasebo] group until 7.9 months, the cancer advances, period, with the sorafenib group 5.5 months, with the [purasebo] group they were 2.8 months lifetime of the sorafenib group (median) vis-a-vis being 10.7 months. Quite, you could obtain the satisfactory result, test early ended. As for the side effect you say that it was same with both groups.

　In the meeting, when the colon which has liver transfer (the colon) with the rectum cancer patient, combined use chemotherapy (FOLFOX4) it executes on operation front and back recurrence risk of the liver tumor 30% was shown also the fact that it decreases. The Ambroise Pare hospital which does (Paris) Bernard Nordlinger doctor has expressed research that it becomes the standard remedy where is new with the colon rectum cancer patient where this method has liver transfer. Presently, annual 1,000,000 is diagnosed the colon rectum cancer, can see liver transfer half. Removing the liver tumor with operation, 5 annual survival ratio has been restricted to the 30~35%.